India’s first indigenous COVID-19 vaccine ‘Covaxin’ will now be sold and manufactured in Canada as Bharat Biotech has extended its tie-up with biopharmaceutical company Ocugen Inc to expand to the Canadian market after the US. Bharat Biotech will have exclusive co-development, manufacturing, and commercialisation rights of Covaxin in Canada, in addition to its existing United States rights.
According to Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen Dr Shankar Musunuri, Covaxin is yet to get approval for emergency use in the US and Canada.
